Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ZTS
CUSIP98978V10
Phone973-822-7000
Debt
Debt-to-Equity Ratio2.50
Current Ratio4.38
Quick Ratio2.92
Price-To-Earnings
Trailing P/E Ratio38.11
Forward P/E Ratio29.79
P/E Growth1.88
Sales & Book Value
Annual Sales$5.31 billion
Price / Sales8.30
Cash Flow$2.9214 per share
Price / Cash31.31
Book Value$3.67 per share
Price / Book24.92
Profitability
EPS (Most Recent Fiscal Year)$2.40
Net Income$864 million
Net Margins19.95%
Return on Equity72.30%
Return on Assets15.96%
Miscellaneous
Employees9,200
Outstanding Shares481,820,000
Market Cap$44.18 billion
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Tuesday, May 15th. Stockholders of record on Friday, July 20th will be given a dividend of $0.126 per share on Tuesday, September 4th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, July 19th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) posted its earnings results on Thursday, August, 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.71 by $0.06. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.38 billion. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the company posted $0.53 earnings per share. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share (EPS) guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.05. The company issued revenue guidance of $5.7-5.8 billion, compared to the consensus revenue estimate of $5.74 billion.
What price target have analysts set for ZTS?
16 analysts have issued 12 month price targets for Zoetis' stock. Their forecasts range from $77.00 to $103.00. On average, they expect Zoetis' stock price to reach $91.0714 in the next year. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
What are Wall Street analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. Cantor Fitzgerald analysts commented, "We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98." (5/16/2018)
- 2. According to Zacks Investment Research, "Zoetis faces stiff competition from other animal health medicines and vaccines companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly), Bayer Animal Health (the animal health division of Bayer) and Boehringer Ingelheim Animal Health (the animal health division of Boehringer Ingelheim). Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products.In addition, companion animal health products are often directly prescribed and dispensed by veterinarians. The swine business is being impacted by competition for Fostera. These competitive pressures could adversely affect the company’s business and operating results. However, shares of the company have outperformed the industry in the last six months." (1/13/2018)
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN) and ASTELLAS PHARMA/ADR (ALPMY).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 67)
- Mr. Glenn C. David, Exec. VP & CFO (Age 46)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
- Mr. Clinton A. Lewis Jr., EVP and Pres of International Ops., Commercial Devel., Global Genetics & Aquatic Health (Age 51)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 47)
Has Zoetis been receiving favorable news coverage?
News coverage about ZTS stock has been trending somewhat negative this week, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a news impact score of -0.01 on Accern's scale. They also gave news headlines about the company an impact score of 45.15 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Zoetis.
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.71%), Morgan Stanley (3.07%), Polen Capital Management LLC (1.93%), Massachusetts Financial Services Co. MA (1.57%), Brown Advisory Inc. (1.37%) and Wells Fargo & Company MN (1.32%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Michael B Mccallister, Roman Trawicki and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.
Which institutional investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, American Century Companies Inc., Millennium Management LLC, Jennison Associates LLC, Morgan Stanley, Brown Advisory Inc. and Waddell & Reed Financial Inc.. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki and Roxanne Lagano. View Insider Buying and Selling for Zoetis.
Which institutional investors are buying Zoetis stock?
ZTS stock was acquired by a variety of institutional investors in the last quarter, including Banque Pictet & Cie SA, Janus Henderson Group PLC, Bank of Montreal Can, New York State Teachers Retirement System, Marshall Wace LLP, Wells Fargo & Company MN, Bank of New York Mellon Corp and Polen Capital Management LLC. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $91.47.
How big of a company is Zoetis?
Zoetis has a market capitalization of $44.18 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
